Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Rocket Lab has given back most of last week's 7.7% gain in a single week, falling 14.4% to $64.22 as a broad sector selloff met a fresh round of analyst target cuts.
The analyst picture is the clearest explanation for the week's move. TD Cowen slashed its price target from $120 to $90 on October 9, maintaining its Buy rating but signalling a meaningful step back in conviction. Barclays initiated the same day with an Overweight and an $85 target, below the current consensus mean of $106. Citigroup's $105 Buy initiation from October 1 is now the bullish anchor, but with the stock at $64.22 the entire analyst community is pointing well above current levels. The consensus direction remains firmly positive, with no downgrades visible in recent activity and multiple initiations in the past month from Citigroup, Barclays and Raymond James, all at Buy-equivalent ratings. What changed this week is the size of the implied discount: TD Cowen's cut alone moved the goalposts by $30, and Barclays entered at a target that would be a 32% premium to today's close, not the 66% gap the consensus mean implies.
Short positioning tells a story that is broadly consistent with last week's note, though the data has shifted slightly. Short interest edged up 3.2% on October 13 to 46.2 million shares, representing 8.6% of the free float. That is marginally lower than the 8.75% reported last week, as covered positions from earlier in October partially offset the day's increase. The month-on-month rise of 4.9% confirms the rebuilding trend remains intact. The lending market is still far from squeeze territory. Availability has tightened modestly to 250%, down from 264% a week ago and the lowest reading in the 30-day window, but still means roughly two and a half shares are available to borrow for every one out on loan. The 52-week tightest reading was 223%, so there is room to run before the borrow market becomes a constraint. Cost to borrow remains low at 0.44%, down slightly on the week. Options positioning adds a mild defensive lean: the put/call ratio at 0.74 is just above its 20-day average of 0.73 and less than one standard deviation from the mean, not an alarming reading but consistent with investors holding moderate protection into an uncertain tape.
The bull and bear cases are well-defined. Bulls point to a $2.36 billion backlog, more than $800 million in bookings since the June quarter end, a 92-launch success record for Electron, and the pending Iridium acquisition that would add 2.55 million subscribers and roughly $300 million in free cash flow. The Iridium deal also carries an index rebalance dimension: ORTEX forecasts an 84% probability of a share-count increase in the Russell 1000 and Russell 3000 associated with the acquisition, and a 65% probability for the MSCI World and FTSE All-World, with estimated trade dates around June 2027. These are forecasts, not announcements, and dates are estimated. Bears focus on the Q3 guidance, where GAAP gross margin of 29% to 31% came in below consensus and adjusted EBITDA is expected at negative $17 million to negative $23 million. Valuation is demanding at a trailing PE above 1,500 and EV/EBITDA above 500, multiples that compress quickly when sentiment shifts. The factor scorecard captures this tension: EPS momentum over 30 days ranks in the 100th percentile, EPS surprise at the 90th, but the short score rank sits at just the 15th percentile, reflecting that relative to the broader universe, short positioning is far from extreme.
Peer context confirms this was not an RKLB-specific week. FLY fell 19.7% over the same period and LUNR dropped 19.1%. RDW was off 13.7% and SATL fell 17.4%. The selloff was broad across the launch and space-systems cohort, which means the stock's 14.4% decline, while painful, is roughly in line with where its closest correlated peers landed.
On the insider front, CFO Adam Spice sold approximately $9.9 million of stock on October 1 across three transactions, all conducted under a pre-arranged 10b5-1 plan. Plan sales carry less informational weight than discretionary ones, but the 90-day net insider selling of around $313 million is a figure worth noting as context. The next earnings print is scheduled for November 10, 27 days away, which means the current positioning and analyst revisions will be tested relatively quickly.
See the live data behind this article on ORTEX.
Open RKLB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
